St. Jude Medical, Inc. STJ recently announced the European launch of its new upgradeable and recharge-free Spinal Cord Stimulation (SCS) System – Proclaim Elite. The approval includes conditional magnetic resonance (MR) labeling for the Proclaim Elite SCS system, which will facilitate safe MRI scanning for head and extremity of patients.
The Proclaim Elite SCS System also comprises the new innovative clinician programmer, through which physicians can program as well as regulate their patient’s SCS therapy with an Apple AAPL iPad mini mobile digital device.
It is to be noted that St. Jude has already received FDA approval for the product last month. We believe that the Proclaim Elite SCS System will be a significant addition to the company’s expanding product portfolio, which will help the company gain better market traction.
In Aug 2015, St. Jude received CE Mark approval for magnetic resonance imaging (MRI) conditional labeling for the company’s Prodigy MRI chronic pain system with select leads. Once rolled out, the Prodigy MRI chronic pain system will be the smallest MR-conditional rechargeable implantable pulse generator (IPG) in the market.
This July, the company received approval of MR-conditional labeling for the company’s Penta 5-column paddle lead for spinal cord stimulation (SCS) therapy. St. Jude’s Penta 5-column paddle lead, which offers small electrodes in a five-column array lead, stimulates nerve and enables dermatomal activation to treat complex multifocal pain.
In June, St. Jude announced CE Mark approval and the European launch of its Invisible Trial System – an app-based neuromodulation programming system which employs Apple and Bluetooth’s wireless technology. By leveraging the Apple iPod touch and iPad mini technology, the system relies on Bluetooth communication to help chronic pain patients better assess the effect of spinal cord stimulation therapy prior to permanent implantation.
Moreover, with the takeover of Spinal Modulation (completed in May 2015), St. Jude took significant steps toward boosting its product portfolio for the treatment of chronic pain. In June, St. Jude announced positive data from the ACCURATE study which validated the superiority of Spinal Modulation’s Axium Neurostimulator System over traditional spinal cord stimulation (SCS).
Zacks Rank & Key Picks
St. Jude carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the same space include Masimo MASI and Natus Medical BABY. Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment